Negative impact of sedation on esophagogastric junction evaluation during esophagogastroduodenoscopy

Table 1 Baseline characteristics of subjects n (%)

	No sedation	Midazolam	Propofol	P value
	(n = 35)	(n = 35)	(n = 33)
Age, yr	61 ± 9.2	57.5 ± 10.5	56.5 ± 10.9	0.132
Male	17 (48.6)	21 (60.0)	12 (36.4)	0.152
Weight, kg	60.6 ± 9.2	52.5 ± 8.9	63.5 ± 12.4	0.506
Height, cm	161.5 ± 6.7	163.2 ± 9.9	160.3 ± 8.1	0.340
Abdomen, cm	81.8 ± 10.0	85.8 ± 7.5	84.8 ± 10.6	0.194
Hip, cm	92.7 ± 5.8	94.4 ± 6.1	95.1 ± 6.3	0.260
BMI	23.2 ± 3.0	23.44 ± 2.6	24.5 ± 3.1	0.143
Comorbidity
Hypertension	10 (28.6)	7 (20.0)	9 (27.3)	0.717
Diabetes mellitus	2 (5.7)	5 (14.3)	8 (24.2)	0.103
Cardiovascular accident	1 (2.9)	1 (2.9)	1 (3.0)	1.000
Ischemic heart disease	2 (5.7)	0 (0.0)	2 (6.1)	0.277
Liver disease	2 (5.7)	1 (2.9)	2 (6.1)	0.867
Malignancy	1 (2.9)	2 (5.7)	0 (0.0)	0.771

BMI: Body mass index.